NAS:ZIOP (USA) Also Trade In: Germany

ZIOPHARM Oncology Inc $ 3.76 0 (0%)

Volume:
1,188
Avg Vol (1m):
2,388,308
Market Cap $:
805.73 Mil
Enterprise Value $:
672.78 Mil
P/E (TTM):
0.00
P/B:
5.52
Warning! GuruFocus has detected 3 Severe warning signs with ZIOP. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for ZIOP (ZIOPHARM Oncology Inc) from 2005 to Jan 21 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. ZIOPHARM Oncology stock (ZIOP) PE ratio as of Jan 21 2021 is 0. More Details

ZIOPHARM Oncology PE Ratio (TTM) Chart

EMBED

ZIOPHARM Oncology PE Ratio (TTM) Historical Data

Total 1254
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
ZIOPHARM Oncology PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2021-01-210.0 2020-11-190.0
2021-01-200.0 2020-11-180.0
2021-01-190.0 2020-11-170.0
2021-01-180.0 2020-11-160.0
2021-01-150.0 2020-11-130.0
2021-01-140.0 2020-11-120.0
2021-01-130.0 2020-11-110.0
2021-01-120.0 2020-11-100.0
2021-01-110.0 2020-11-090.0
2021-01-080.0 2020-11-060.0
2021-01-070.0 2020-11-050.0
2021-01-060.0 2020-11-040.0
2021-01-050.0 2020-11-030.0
2021-01-040.0 2020-11-020.0
2021-01-010.0 2020-10-300.0
2020-12-310.0 2020-10-290.0
2020-12-300.0 2020-10-280.0
2020-12-290.0 2020-10-270.0
2020-12-280.0 2020-10-260.0
2020-12-250.0 2020-10-230.0
2020-12-240.0 2020-10-220.0
2020-12-230.0 2020-10-210.0
2020-12-220.0 2020-10-200.0
2020-12-210.0 2020-10-190.0
2020-12-180.0 2020-10-160.0
2020-12-170.0 2020-10-150.0
2020-12-160.0 2020-10-140.0
2020-12-150.0 2020-10-130.0
2020-12-140.0 2020-10-120.0
2020-12-110.0 2020-10-090.0
2020-12-100.0 2020-10-080.0
2020-12-090.0 2020-10-070.0
2020-12-080.0 2020-10-060.0
2020-12-070.0 2020-10-050.0
2020-12-040.0 2020-10-020.0
2020-12-030.0 2020-10-010.0
2020-12-020.0 2020-09-300.0
2020-12-010.0 2020-09-290.0
2020-11-300.0 2020-09-280.0
2020-11-270.0 2020-09-250.0
2020-11-260.0 2020-09-240.0
2020-11-250.0 2020-09-230.0
2020-11-240.0 2020-09-220.0
2020-11-230.0 2020-09-210.0
2020-11-200.0 2020-09-180.0

ZIOPHARM Oncology PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Industry Healthcare » Biotechnology » NAICS : 325412 NAICS : 2834
Traded in other countries WEK.Germany ZIOP.USA
Address One First Avenue, Parris Building 34, Navy Yard Plaza, Boston, MA, USA, 02129
ZIOPHARM Oncology Inc is a biotechnology company that acquires, develops, and commercializes cancer therapies. Its preclinical and clinical pipeline focuses on treating hematological and solid tumor malignancies using cellular therapeutics. Ziopharm engages in gene therapy systems with its partner Intrexon and collaborators at the University of Texas. To fund the development of its product candidates, the company engages in contractual arrangements with licensing partners both in the United States and abroad.